From the Knight Lab at UCSF
(2018). Regulation of body temperature by the nervous system. Neuron 98 (1): 31–48. Published online 04 April 2018. [pdf]
(2018). A spotlight on appetite. Neuron 97 (4): 739–741. Published online 21 February 2018. [pdf]
(2017). The forebrain thirst circuit drives drinking through negative reinforcement. Neuron 96 (6): 1272–1281. Published online 20 December 2017. [pdf]
(2017). Linking smell to metabolism and aging. Science 358 (6364): 718–719. Published online 10 November 2017. [pdf]
(2017). Dynamics of gut-brain communication underlying hunger. Neuron 96 (2): 461–475. Published online 11 October 2017. [pdf]
(2017). Neural circuits underlying thirst and fluid homeostasis. Nature Reviews Neuroscience 18 (8): 459–469. Published online 22 June 2017. [pdf]
(2017). Identification of preoptic sleep neurons using retrograde labelling and gene profiling. Nature 545 (7655): 477–481. Published online 17 May 2017. [pdf]
(2016). Warm-sensitive neurons that control body temperature. Cell 167 (1): 47–59. Published online 08 September 2016. [pdf]
(2016). Hunger neurons drive feeding through a sustained, positive reinforcement signal. eLife 5: e18640. Published online 24 August 2016. [pdf]
(2016). Rapid sensing of dietary amino acid deficiency does not require GCN2. Cell Reports 16 (8): 2051–2052. Published online 23 August 2016. [pdf]
(2016). Thirst neurons anticipate the homeostatic consequences of eating and drinking. Nature 537 (7622): 680–684. Published online 03 August 2016. [pdf]
(2016). Making sense of the sensory regulation of hunger neurons. BioEssays 38 (4): 316–324. Published online 22 February 2016. [pdf]
(2015). Re-examination of dietary amino acid sensing reveals a GCN2-independent mechanism. Cell Reports 13 (6): 1081–1089. Published online 29 October 2015. [pdf]
(2015). Sensory detection of food rapidly modulates arcuate feeding circuits. Cell 160 (5): 829–841. Published online 19 February 2015. [pdf]
Earlier Work
(2015). Downregulation of MYCN through PI3K inhibition in mouse models of pediatric neural cancer. Frontiers in Oncology 5: 111. Published online 12 May 2015. [pdf]
(2014). A critical role for mTORC1 in erythropoiesis and anemia. eLife 3: e01913. Published online 08 September 2014. [pdf]
(2014). Ablation of AgRP neurons impairs adaption to restricted feeding. Molecular Metabolism 3 (7): 694–704. Published online 10 July 2014. [pdf]
(2014). Molecular profiling of neurons based on connectivity. Cell 157 (5): 1230–1242. Published online 22 May 2014. [pdf]
(2012). Molecular profiling of activated neurons by phosphorylated ribosome capture. Cell 151 (5): 1126–1137. Published online 20 November 2012. [pdf]
(2011). For a PDK1 inhibitor, the substrate matters. Biochemical Journal 433 (2): e1–e2. Published online 15 January 2011. [pdf]
(2010). Hyperleptinemia is required for the development of leptin resistance. PLoS One 5 (6): e11376. Published online 29 June 2010. [pdf]
(2010). Small molecule inhibitors of the PI3-kinase family. Current Topics in Microbiology & Immunology 347: 263–278. Published online 07 May 2010. [pdf]
(2010). Discovery of dual inhibitors of the immune cell PI3Ks p110δ and p110γ: a prototype for new anti-inflammatory drugs. Chemistry & Biology 17 (2): 123–134. Published online 25 February 2010. [pdf]
(2010). Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 10 (2): 130–137. Published online 01 February 2010. [pdf]
(2009). Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113 (22): 5549–5557. Published online 24 March 2009. [pdf]
(2009). Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biology 7 (2): e1000038. Published online 10 February 2009. [pdf]
(2009). EGFR signals to mTOR through PKC and independently of Akt in glioma. Science Signaling 2 (55): ra4. Published online 27 January 2009. [pdf]
(2009). Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Research 69 (2): 565–572. Published online 15 January 2009. [pdf]
(2008). Dual inhibition of PI3Kα and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Research 68 (20): 8361–8368. Published online 15 October 2008. [pdf]
(2008). Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chemical Biology 4 (11): 691–699. Published online 12 October 2008. [pdf]
(2008). Genetic or pharmaceutical blockade of p110δ phosphoinositide 3-kinase enhances IgE production. Journal of Allergy & Clinical Immunology 122 (4): 811–819. Published online 04 October 2008. [pdf]
(2008). PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation. Cancer Research 68 (19): 8127–8136. Published online 30 September 2008. [pdf]
(2008). Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. Journal of Clinical Investigation 118 (9): 3038–3050. Published online 14 August 2008. [pdf]
(2008). Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110α. Cancer Cell 14 (2): 180–192. Published online 11 August 2008. [pdf]
(2008). Activity of the p110-α subunit of phosphatidylinositol-3-kinase is required for activation of epithelial sodium transport. American Journal of Physiology: Renal Physiology 295 (3): F843–F850. Published online 23 July 2008. [pdf]
(2008). PI-103, a dual inhibitor of class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22 (9): 1698–1706. Published online 12 June 2008. [pdf]
(2008). T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proceedings of the National Academy of Sciences 105 (22): 7797–7802. Published online 28 May 2008. [pdf]
(2008). A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochemical Journal 415 (1): 97–110. Published online 22 May 2008. [pdf]
(2008). Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Molecular Cancer Therapeutics 7 (4): 841–850. Published online 15 April 2008. [pdf]
(2008). Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling. Biochemistry 47 (6): 1599–1607. Published online 19 January 2008. [pdf]
(2008). Maintenance of hormone-sensitive phosphoinositide pools in the plasma membrane requires phosphatidylinositol 4-kinase IIIα. Molecular Biology of the Cell 19 (2): 711–721. Published online 12 December 2007. [pdf]
(2007). A membrane capture assay for lipid kinase activity. Nature Protocols 2 (10): 2459–2466. Published online 04 October 2007. [pdf]
(2007). A remodelled protease that cleaves phosphotyrosine substrates. Journal of the American Chemical Society 129 (38): 11672–11673. Published online 06 September 2007. [pdf]
(2007). A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Research 67 (17): 7960–7965. Published online 01 September 2007. [pdf]
(2007). HIV-1 Nef assembles a Src family kinase-ZAP-70/Syk-PI3K cascade to downregulate cell surface MHC-I. Cell Host & Microbe 1 (2): 121–133. Published online 18 April 2007. [pdf]
(2007). Chemically targeting the PI3K family. Biochemical Society Transactions 35 (2): 245–249. Published online 01 April 2007. [pdf]
(2007). Chemical genetics: where genetics and pharmacology meet. Cell 128 (3): 425–430. Published online 08 February 2007. [pdf]
(2006). Phosphatidylinositol 4-kinase IIIβ regulates the transport of ceramide between the endoplasmic reticulum and golgi. Journal of Biological Chemistry 281 (47): 36369–36377. Published online 26 September 2006. [pdf]
(2006). To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. Journal of Cell Biology 174 (3): 437–445. Published online 24 July 2006. [pdf]
(2006). A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (5): 341–349. Published online 15 May 2006. [pdf]
(2006). Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Molecular Cancer Therapeutics 5 (4): 885–892. Published online 28 April 2006. [pdf]
(2006). A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125 (4): 733–747. Published online 27 April 2006. [pdf]
(2006). Knock-outs and inhibitors: one and the same?. Blood 107 (2): 420–421. Published online 09 January 2006. [pdf]
(2005). Features of selective kinase inhibitors. Cell Chemical Biology 12 (6): 621–637. Published online 24 June 2005. [pdf]
(2005). Targeting the gatekeeper residue in phosphoinositide 3-kinases. Bioorganic & Medicinal Chemistry 13 (8): 2825–2836. Published online 10 March 2005. [pdf]
(2004). Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorganic & Medicinal Chemistry 12 (17): 4749–4759. Published online 20 July 2004. [pdf]
(2003). Phosphospecific proteolysis for mapping sites of protein phosphorylation. Nature Biotechnology 21 (9): 1047–1054. Published online 17 August 2003. [pdf]
(2003). A novel pseudoknot element is essential for the action of a yeast telomerase. Genes & Development 17 (14): 1779–1788. Published online 27 June 2003. [pdf]
(2000). Another possible mechanism of resistance to STI571. Blood 96 (12): 4003–4005. Published online 01 December 2000. [pdf]
